Helmholtz Zentrum München Deutsches Forschungszentrum

An international team of researchers have discovered a new genetic variant that is responsible for close to 7% of all cases of diabetes in Greenland. People with this form of diabetes, caused by the high-impact genetic variant, may require special treatment, which will be possible through improved genetic screening of patients. Not all diabetes is the same, and it goes well beyond the two main classifications, type 1 and type 2. Monogenic diabetes refers to forms of diabetes caused by single genetic variations. Maturity-onset diabetes of the young (MODY) is the most common clinical subdivision of monogenic diabetes, with diabetes typically arising in young adulthood. Now, an international team of researchers have discovered a new variant of the HNF1A gene, which can cause MODY that accounts for almost seven percent of all cases of diabetes in Greenland and is found nowhere else in the world. "We were excited to make this discovery of a new genetic variant that is responsible for close to seven percent all cases of diabetes in Greenland. Discoveries like these, which was made possible thanks to a generous collaboration with the Greenlandic people, help us better understand the complexity of diabetes" says Professor Torben Hansen from the Novo Nordisk Foundation Center for Basic Metabolic Research at the University of Copenhagen. He led the research together with Professors Anders Albrechtsen and Ida Moltke from the Department of Biology at the University of Copenhagen. Potential for precision medicine People with HNF1A-MODY are often misdiagnosed with either type 1 or type 2 diabetes and given medication that is not effective. Instead, HNF1A-MODY is most effectively treated with tablet therapy with sulphonylurea, which is rarely used today in the treatment of type 2 diabetes. Therefore, researchers are hopeful that this discovery will pave the way for precision treatment in Greenland. As monogenic diabetes is inherited, genetic tests can reveal if other family members also have the same type of diabetes. "This discovery is good news for the treatment of diabetes in Greenland, because most people with MODY can be treated with a simple and cheap tablet treatment and avoid insulin and other more complex forms of diabetes treatment. Therefore, we now offer genetic testing for MODY to all our patients with diabetes, and when we find people with HNF1A-MODY, we systematically offer that family members are also tested," says senior physician and professor Marit Eika Jørgensen at the Steno Diabetes Center Greenland. Marit Eika Jørgensen coordinated the research in Greenland, which involved more than 4,000 Greenlanders. Monogenic diabetes more common in Greenland than in Western populations Together with a previously described high-impact variant TBC1D4 variant, close to 1 in 5 Greenlanders with diabetes are carriers of common high-impact variants. Monogenic diabetes is, therefore, far more frequent in Greenland than in Western populations, where monogenic diabetes is estimated to account for only around 1 in 50 cases of diabetes. "This discovery clearly demonstrates how common diseases are much more complex than we previously thought. Thanks to the breakthroughs in genetic research and data science capabilities, many people around the world may benefit from new personalized medicine approaches that take ancestral, genetic, and environmental backgrounds into account," says PhD Student Anne Cathrine Baun Thuesen from CBMR, who was co-first author together with Frederik Filip Stæger from the Department of Biology at the University of Copenhagen. This research is a collaboration between researchers at the University of Copenhagen, University of Greenland, Steno Diabetes Center Greenland, Steno Diabetes Center Copenhagen, the University of Bergen, Haukeland University Hospital Bergen, Max Planck Institute for Metabolism Research, Helmholtz Zentrum München, University of Southern Denmark, TUM School of Medicine Münich, and the Western Norway University of Applied Sciences.

声明：因水平有限，错误不可避免，或有些信息非最及时，欢迎留言指出。本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及）;本文不构成任何投资建议。小编：期待华为入局，给中国医药圈带来新生力量，助力中国新药发展！近期，云南白药发布公告， 云南白药集团股份有限公司与华为技术有限公司于2022年7月23日在福建省福州市签订《人工智能药物研发全面合作协议》。公司将与华为技术在人工智能药物研发领域，开展广泛的交流和合作，探索联合科研创新的机制，扩大双方合作的广度和深度，包括但不限于大小分子设计、相关病症、数据库开发等。合作内容1、人工智能药物研发云南白药凭借在中药及植物领域多年积累，沉淀了行业独有的植物标本数据库、云南天然提取物的数据库、国外天然产物库。华为技术在AI辅助药物研发、云计算、人工智能等方面具有丰富的经验和案例。 双方探索联合科研创新的机制，在AI、药物研发领域开展广泛的交流和合作，扩大双方合作的广度和深度。包括但不限于大小分子设计、相关病症、数据库开发等。2、其他合作事项：双方达成一致的其他合作事项，在此合作协议基础上另行签订补充协议进行明确。   华为已经早早入局药物研发领域更早，据华为云公众号消息，2021年9月23日，华为全联接2021隆重开幕，华为高级副总裁、华为云CEO、消费者云服务总裁张平安发表“深耕数字化，一切皆服务”主题演讲，并重磅发布了华为云盘古药物分子大模型。华为云盘古药物分子大模型是“盘古家族”的新成员，是专门面向药物研发领域推出的预训练大模型，旨在帮助医药公司开启AI辅助药物研发的新模式。华为云盘古药物分子大模型四大技术和创新能力提出了针对化合物表征学习的全新深度学习网络架构进行了超大规模化合物表征模型训练生成了拥有1亿个新化合物的数据库在20余项药物发现任务上实现性能最优（SOTA）详见：华为云发布盘古药物分子大模型，开启AI药物研发新模式   不仅仅华为，互联网巨头们BAT（百度、阿里、腾讯）、FB 等IT巨头，纷纷进军医药产业，在AI制药领域加大布局力度！百图生科（BioMap）是生物计算驱动的生命科学平台公司，由百度创始人李彦宏发起创立，致力于通过长周期、大规模的投入，通过先进AI技术+前沿生物技术的融合创新，打造新型多组学检测分析、高通量实验模拟、智能化分子发现引擎，加速新型药物和诊断产品的研发，造福人类健康。全球健康药物研发中心GHDDI与阿里云合作开发人工智能药物研发和大数据平台；正大天晴与阿里云合作，AI制药提高化合物筛选准确率20%。阿里云的医疗AI此前已在基因测序、甲状腺结节识别、肺结节识别、数字化模拟临床实验等领域发挥作用。腾讯多次参与投资AI制药公司，晶泰科技等；还直接布局AI新药研发领域，发布「云深智药」平台，新基建助力药物研发全流程。Facebook AI和德国环境健康研究中心Helmholtz Zentrum München引入一种新方法，该方法将有助于加速发现有效的新药组合。来源：上市公司公告资料来源：--华为官网，https://www.huawei.com--云南白药官网，http://www.yunnanbaiyao.com.cn--上市公司公告--华为云发布盘古药物分子大模型，开启AI药物研发新模式--http://www.doc88.com/p-20759413282827.html--https://www.huaweicloud.com/ei/--https://www.huaweicloud.com/product/eihealth.html--https://www.nmpa.gov.cn/xxgk/ggtg/qtggtg/20201013155906186.html--http://www.biomap.com/--https://mp.weixin.qq.com/s/UYvnBXEzWcFRgSOb1fMfjA--https://www.alihealth.cn/--https://developer.aliyun.com/article/635126--https://ai.tencent.com/--https://www.jingtaikeji.com/zh-hans/news/XtalPi-series-c/--https://mp.weixin.qq.com/s/2C2vzpdIiw8fP7aXhmDCYw--https://about.fb.com/news/2021/04/ai-predicts-effective-drug-combinations-to-fight-complex-diseases-faster/--https://www.helmholtz-muenchen.de/en/helmholtz-zentrum-muenchen/index.html等

DUBLIN, June 14, 2022 /PRNewswire/ -- The "Global Vaccine Partnering Terms and Agreements 2014-2022: Deal Trends, Players and Financials" report has been added to ResearchAndMarkets.com's offering. This report contains a comprehensive listing of all vaccine partnering deals announced since January 2014, including financial terms where available, including over 1100 links to online deal records of actual vaccine partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Trends in vaccine and adjuvant partnering deals Partnering agreement structure Partnering contract documents Top deals by value Most active dealmakers Average deal terms for vaccines The report takes readers through the vaccine deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering vaccine partnering deals. The report presents average financial deal terms values for vaccine deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals. The middle section of the report explores the leaders in the vaccine partnering field; both the leading deal values and leading players are reported allowing readers to see who is succeeding in this growing market. This chapter also looks at the contributions by the big pharma and big biotech companies of the world in terms of deals made. One of the key highlights of the report is that over 1100 online deals records of actual vaccine deals as disclosed by the deal parties are included towards the end of the report in a directory format that is easy to reference. Each deal links via Weblink to an online version and all these deals are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), specific therapy and technology focus. In addition the report includes actual contract documents where available as submitted to the Securities Exchange Commission by companies and their deal partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. Finally the report concludes by looking into the future of vaccine partnering. With so many innovators looking for the next big thing in the field, the report selects companies to watch who are predicted to become big in the field based on their current dealmaking and financial trends. Throughout the report various tables, figures and graphs are embedded in order to illustrate the trends and partnering activities of the vaccine field. By the end of the report prospective dealmakers will have gained a thorough understanding of the partnering landscape of the vaccine market and will be familiar with the values and structures of the deals being signed within it. Global Vaccine Partnering Terms and Agreements 2014-2022: Deal trends, players and financials includes: Trends in vaccine dealmaking in the biopharma industry since 2014 Access to headline, upfront, milestone and royalty data Access to over 1100 vaccine deal documents The leading vaccine deals by value since 2014 Most active vaccine dealmakers since 2014 The leading vaccine partnering resources Available contracts are listed by: Company A-Z Headline value Stage of development at signing Deal component type Therapy target Specific technology type Analyzing actual contract agreements allows assessment of the following: What are the precise vaccine rights granted or optioned? What is actually granted by the agreement to the partner company? What exclusivity is granted? What is the payment structure for the deal? How are sales and payments audited? What is the deal term? How are the key terms of the agreement defined? How are IPRs handled and owned? Who is responsible for commercialization? Who is responsible for development, supply, and manufacture? How is confidentiality and publication managed? How are disputes to be resolved? Under what conditions can the deal be terminated? What happens when there is a change of ownership? What sublicensing and subcontracting provisions have been agreed? Which boilerplate clauses does the company insist upon? Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? Which jurisdiction does the company insist upon for agreement law? Key Topics Covered: Executive Summary Chapter 1 - Introduction Chapter 2 - Trends in Vaccines dealmaking 2.1. Introduction 2.2. Vaccines partnering over the years 2.3. Most active Vaccines dealmakers 2.4. Vaccines partnering by deal type 2.5. Vaccines partnering by therapy area 2.6. Deal terms for Vaccines partnering 2.6.1 Vaccines partnering headline values 2.6.2 Vaccines deal upfront payments 2.6.3 Vaccines deal milestone payments 2.6.4 Vaccines royalty rates Chapter 3 - Leading Vaccines deals 3.1. Introduction 3.2. Top Vaccines deals by value Chapter 4 - Most active Vaccines dealmakers 4.1. Introduction 4.2. Most active Vaccines dealmakers 4.3. Most active Vaccines partnering company profiles Chapter 5 - Vaccines contracts dealmaking directory 5.1. Introduction 5.2. Vaccines contracts dealmaking directory Chapter 6 - Vaccines dealmaking by technology type Appendices Appendix 1 - Vaccines deals by company A-Z Appendix 2 - Vaccines deals by stage of development Discovery Preclinical Phase I Phase II Phase III Regulatory Marketed Formulation Appendix 3 - Vaccines deals by deal type Asset purchase Assignment Bigpharma outlicensing Co-development Collaborative R&D Co-market Co-promotion CRADA Cross-licensing Development Distribution Equity purchase Evaluation Grant Joint venture Licensing Manufacturing Marketing Material transfer Option Promotion Research Settlement Spin out Sub-license Supply Technology transfer Termination Appendix 4 - Vaccines deals by therapy area Anaesthetics Cardiovascular Central Nervous System Dental Gastrointestinal Hematology Immunology Infectives Metabolic Musculoskeletal Oncology Ophthalmics Orphan disease Pediatrics Psychiatry Respiratory Appendix 5 -Deal type definitions Appendix 6 - Further reading on dealmaking Companies Mentioned 2A 3D Medicines 3SBio 4D Pharma A*STAR' Institute of Molecular and Cell Biology ABEC ABIVAX AGC Biologics Agenus Bio Agilvax AIM ImmunoTech Akers Biosciences Amyris Analytical Bio-Chemistry Laboratories AnGes MG Anixa Biosciences Battelle Batu Biologics CCT Research Celldex Therapeutics Cellular Biomedicine Celonic Diavax Biosciences Diaxonhit DNA Script DNAtrix Dr. Reddy's Laboratories Frederick National Laboratory For Cancer Research Fred Hutchinson Cancer Research Center Fujifilm GISCAD Foundation GlaxoSmithKline Hefei Sageland Biotechnology Helmholtz Zentrum Munchen MinervaX Recipharm Sanofi Wyss Institute Xenetic Biosciences XstalBio Y-Biologics Y-mAbs Therapeutics Yale University Yamaguchi University Yisheng Biopharma Zenoaq Zoetis Zolovax Zuellig Pharma China Zydus Cadila ZYUS Life Sciences For more information about this report visit Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1904 Fax (outside U.S.): +353-1-481-1716 SOURCE Research and Markets